The calpain system, including the proteolytic enzymes μ-calpain and m-calpain and their endogenous inhibitor calpastatin, has been implicated in cancer progression and response to therapy in a limited number of studies and tumour types [15]. The gene discussed is CAPN2; the disease is cancer.